CRIO

Case Study

617-302-9845
sales@clinicalresearch.io
www.clinicalresearch.io

VIDA CLINICAL STUDIES: HIGHEST ENROLLING SITE IN HIGH-PROFILE VACCINE STUDY

OVERVIEW

Vida Clinical Studies is a high-performing global site network with a strong presence in the United States and Lebanon. Led by founder and president Hisham Atriss, Vida Clinical Studies consists of four sites within the United States and one site in Lebanon. Their flagship site is located in Dearborn Heights, MI, where their small, tight-knit team is dedicated to meeting the needs of their surrounding community.

Thanks to Dearborn's proximity to diverse populations in the greater Detroit area, Vida Clinical Studies has access to a large pool of racially and ethnically diverse subjects. To maximize this opportunity, Vida Clinical Studies invested in patient education around clinical research and how to participate, which generated significant interest in their studies from the community. To ensure they could manage the high volume of interest effectively, the Dearborn Heights team of 7 coordinators, 2 regulatory staff, and 3 primary investigators adopted CRIO eSource, a system that empowers teams to work at the highest level of efficiency and accuracy.

Vida Clinical Studies was recently awarded a high-profile RSV vaccine study. Thanks to the adoption of CRIO, the team was able to successfully optimize their research appointments and conduct the study with internal quality control measures. **In just 3.5 months, they enrolled an impressive 388 patients, showcasing the power of efficient data management and study execution with CRIO.**

CHALLENGE

Vida Clinical Studies was awarded a high-enrolling vaccine study, for which they would need to enroll patients quickly and in large quantities to be successful. With a lean team and a large patient database, Vida Clinical Studies needed to find a way to process patients quickly enough to meet their target.

VIDA CLINICAL STUDIES: HIGHEST ENROLLING SITE IN HIGH-PROFILE VACCINE STUDY

SOLUTION

Adopting eSource

Vida Clinical Studies, as a high-volume site, recognized the need to incorporate technology into their workflows to streamline their operations. **Using paper source posed challenges**, such as messy handwriting and large piles of papers, that made it difficult to interpret data points. **These inefficiencies slowed down the site workflow, resulting in errors and increased time spent on reconciling mistakes**.

To address these challenges, Vida Clinical Studies adopted CRIO's eSource technology. With CRIO, compliance to protocols was enforced as coordinators conducted visits. The site implemented technology, such as tablets, enabling coordinators to complete their visits quickly within CRIO eSource. As a result, **Vida Clinical Studies was able to reduce inefficiencies and minimize errors, leading to improved efficiency and accuracy in their operations.**

Streamlined Visit Process

To enroll patients at a high level without sacrificing the quality of collected data, Vida Clinical Studies recognized the need to streamline their visit process. With paper source, quality assurance practices can halt the visit process. Subjects would complete their visit, awaiting payment, but have to wait until the source documents were checked for accuracy by their regulatory team. These delays limited the number of visits that could be completed in a day, resulting in a poor patient experience and site proficiency.

To address these challenges, Vida Clinical Studies implemented quality control measures at the time of each visit, streamlining the visit process. The regulatory staff are able to access the CRIO database and check data as coordinators enter it into eSource. Patients would arrive for their visit, provide any necessary medical history, and undergo necessary testing. By the time the patient is ready to be compensated for the visit, the eSource has simultaneously undergone the internal quality assurance processes.

VIDA CLINICAL STUDIES: HIGHEST ENROLLING SITE IN HIGH-PROFILE VACCINE STUDY

Quicker Visits

To recruit enough patients for their new trial, Vida Clinical Studies needed to streamline the visit process and see more patients each day. **Using CRIO eSource, the protocol was directly translated into eSource and built-in alerts were issued at the time of data entry**, making it easier for coordinators to attain the required information at each visit.

The visit process became seamless once coordinators had all aspects of the protocol built into the source documents, impressing Atriss. This led to a noticeable improvement in the quality of data, reducing the amount of time needed for each visit, and enabling more patients to be seen each hour. Patients no longer needed to return to the site due to errors in following the protocol, ensuring that each visit was conducted within the allotted time.

OUTCOMES

Highest Enrollment in Study

Vida Clinical Studies not only surpassed previous enrollment statistics from a similar study but also emerged as the highest enrolling site in the recent 20-site study.

Atriss reported that “[Vida Clinical Studies] had worked on an identical study previously, for which we enrolled 325 patients in a six-month timeframe. For this study, we enrolled 388 in a three and a half month timeframe, and we attribute this directly to CRIO.”

In this recent 20-site study, Vida Clinical ended up being the highest enroller and even had to halt their recruitment due to their success.

VIDA CLINICAL STUDIES: HIGHEST ENROLLING SITE IN HIGH-PROFILE VACCINE STUDY

Impressively, Vida Clinical Studies does not rely on advertisements or PI databases to recruit patients. Instead, their cultural competency and reputation have created an ecosystem where word-of-mouth referrals bring patients to the site. Patients share their positive experiences with friends and family, generating interest in the community. These interested community members would contact Vida Clinical Studies, eager to participate in the development of new treatments. By this point, the community interest was so high that “the phones would start ringing and we would be able to enroll patients without having to advertise.” This community interest has driven the high performance of Vida Clinical Studies, which now sees up to 22 patients each day. **Their success in enrolling the highest number of patients in the study is a testament to their commitment to patient care, reputation in the community, and adoption of advanced technology, like CRIO.**

Patient Satisfaction

Patients noticed the ease and comfort of their visit once Vida Clinical Studies implemented CRIO. The site is dedicated to cultural understanding within their racially and ethnically diverse community, and patients feel valued.

Atriss emphasized that "when you introduce clinical research to them, educate them, gain their trust, [and] let them experience the process... it builds their trust, and then they share this with their community, with their churches, with their neighborhood, with their family members."

388

PATIENTS ENROLLED IN

3.5

MONTHS

Vida Clinical Studies' commitment to cultural understanding and patient care has led to high levels of patient satisfaction. Patients feel valued, educated, and empowered to participate in clinical research, which has led to a positive impact on the community. By prioritizing patient satisfaction and cultural understanding, Vida Clinical Studies has established itself as a trusted resource for clinical research within the community.

VIDA CLINICAL STUDIES: HIGHEST ENROLLING SITE IN HIGH-PROFILE VACCINE STUDY

Conclusion - The Power of CRIO

Vida Clinical Studies' use of CRIO was instrumental in optimizing their research appointments. By adopting internal quality control measures and streamlining the visit process, the site was able to reduce delays, improve patient experiences, and become the highest enrolling site in a high-profile vaccine study. **The success of enrolling 388 patients in 3.5 months is a testament to the power of eSource technology in clinical research.**

ABOUT THE PROFILE

Hisham Atriss is the owner of Vida Clinical Studies, a clinical research site dedicated to improving healthcare outcomes through innovative research. With over 10 years of experience in the clinical research industry, Hisham is a recognized leader in the field of clinical research management. Hisham's dedication to improving healthcare outcomes through innovative research makes him an invaluable member of the clinical research community.